DrugBiological
Agalsidase beta clinical trials
- studies test it
- 16
- open now
- 1
- in phase 3
- 4
- first study started
- 1999
Keep track of what changes. Save the agalsidase beta studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2002 (2)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2008 | 1 |
| 2012 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
- Phase 3
- 4
- Phase 4
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 0
Genzyme, a Sanofi Company (12) · Sanofi (2) · Bio Sidus SA (1) · ISU Abxis Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses agalsidase beta is read from its arms, and is right about nine times in ten.
Testing it · 16
- Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry DiseaseRecruitingPhase 3ISU Abxis Co., Ltd.NCT06081062Written as Fabagal® (Agalsidase beta)
- Switch Over Study of Biosimilar Agalsidase Beta for Fabry DiseaseCompletedPhase 3Bio Sidus SANCT05843916Written as Recombinant human alpha galactosidase A (agalsidase beta)
- A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of FabrazymeCompletedPhase 4SanofiNCT06019728Written as AGALSIDASE BETA (GZ419828)
- China Post-marketing Surveillance (PMS) Study of Fabrazyme®CompletedPhase 4Genzyme, a Sanofi CompanyNCT05054387Written as Agalsidase beta
- Study of the Effects of Fabrazyme Treatment on Lactation and InfantsTerminatedPhase 4Genzyme, a Sanofi CompanyNCT00230607Written as agalsidase beta
- To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry DiseaseWithdrawnPhase 4SanofiNCT04143958Written as agalsidase beta (GZ419828)
- A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe SymptomsCompletedPhase 3Genzyme, a Sanofi CompanyNCT00701415Written as Agalsidase beta
- A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry DiseaseCompletedPhase 4Genzyme, a Sanofi CompanyNCT00140621Written as Agalsidase beta
- Severe Renal Disease Study in Fabry Patients Treated With FabrazymeTerminatedPhase 2Genzyme, a Sanofi CompanyNCT00837824Written as Fabrazyme (agalsidase beta)
- A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry DiseaseCompletedPhase 2Genzyme, a Sanofi CompanyNCT00196716Written as Fabrazyme (agalsidase beta)
- A Study of Fabrazyme in Pediatric Patients With Fabry DiseaseCompletedPhase 2Genzyme, a Sanofi CompanyNCT00074958Written as Fabrazyme (agalsidase beta)
- A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry DiseaseCompletedPhase 4Genzyme, a Sanofi CompanyNCT00081497Written as agalsidase beta
- A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase BetaCompletedPhase 4Genzyme, a Sanofi CompanyNCT01650779Written as Agalsidase beta
- A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.WithdrawnPhase 4Genzyme, a Sanofi CompanyNCT00312767Written as Fabrazyme (agalsidase beta)
- A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry DiseaseCompletedPhase 4Genzyme, a Sanofi CompanyNCT00074984Written as Fabrazyme (agalsidase beta)
- A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry DiseaseCompletedPhase 3Genzyme, a Sanofi CompanyNCT00074971Written as Fabrazyme (agalsidase beta)
Given in every arm · 1 — agalsidase beta is usual care beside what is tested
As the comparator · 3 — what is tested is compared with agalsidase beta
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseaseActive, not recruitingPhase 3SanofiNCT05280548Written as Agalsidase beta (GZ419828)
- PK/PD Study of 2 Agalsidase Formulations in Single Dose of 1 mg/kg Administered to Healthy Volunteers as IV InfusionCompletedPhase 1Bio Sidus SANCT05343715Written as Fabrazyme (agalsidase beta) 1 mg/kg
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal FunctionCompletedPhase 3ProtalixNCT02795676Written as agalsidase beta
Codes
What other systems call agalsidase beta · ClinicalTrials.gg INT004455
- MeSH (NLM) C459420agalsidase betaConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RZD65TSM9UAGALSIDASE BETAConfirmed FDA, NLM, Wikidata
- RxNorm 338817Confirmed FDA, Wikidata
- Wikidata Q20801779agalsidase betaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74210Agalsidase BetaOne source FDA
- DrugBank DB00103One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C459420 | agalsidase beta | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RZD65TSM9U | AGALSIDASE BETA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 338817 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20801779 | agalsidase beta | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74210 | Agalsidase Beta | One source FDA |
| DrugBank | DB00103 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.